Marianne Dibrino

Array ( [id] => 19954438 [patent_doc_number] => 12324835 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-06-10 [patent_title] => mRNA vaccine encoding fusion antigen against Mpox and severe acute respiratory syndrome coronavirus 2 [patent_app_type] => utility [patent_app_number] => 19/026296 [patent_app_country] => US [patent_app_date] => 2025-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 0 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19026296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19417209 [patent_doc_number] => 20240293332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => Particle Formation And Morphology [patent_app_type] => utility [patent_app_number] => 18/659740 [patent_app_country] => US [patent_app_date] => 2024-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18659740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359372 [patent_doc_number] => 20240261406 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASES [patent_app_type] => utility [patent_app_number] => 18/408259 [patent_app_country] => US [patent_app_date] => 2024-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18408259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157724 [patent_doc_number] => 20240150431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => MHC Multimers, Methods for Their Generation, Labeling and Use [patent_app_type] => utility [patent_app_number] => 18/516130 [patent_app_country] => US [patent_app_date] => 2023-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99473 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18516130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425075 [patent_doc_number] => 12084478 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-09-10 [patent_title] => Fusion peptide inhibitors of human coronavirus 229E [patent_app_type] => utility [patent_app_number] => 18/372634 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2996 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18372634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19060146 [patent_doc_number] => 11939354 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-03-26 [patent_title] => Fusion peptide inhibitors of human coronavirus 229E [patent_app_type] => utility [patent_app_number] => 18/372623 [patent_app_country] => US [patent_app_date] => 2023-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2999 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18372623 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065643 [patent_doc_number] => 20240100069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Methods and Compositions for Treating Amyotrophic Lateral Sclerosis [patent_app_type] => utility [patent_app_number] => 18/241482 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18241482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065643 [patent_doc_number] => 20240100069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Methods and Compositions for Treating Amyotrophic Lateral Sclerosis [patent_app_type] => utility [patent_app_number] => 18/241482 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18241482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887700 [patent_doc_number] => 11866461 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-01-09 [patent_title] => Fusion peptide inhibitors of human coronavirus 229E [patent_app_type] => utility [patent_app_number] => 18/198100 [patent_app_country] => US [patent_app_date] => 2023-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 2936 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18198100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692611 [patent_doc_number] => 20230322925 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS [patent_app_type] => utility [patent_app_number] => 18/189433 [patent_app_country] => US [patent_app_date] => 2023-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86982 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18189433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691020 [patent_doc_number] => 20230321206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/107244 [patent_app_country] => US [patent_app_date] => 2023-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18107244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691020 [patent_doc_number] => 20230321206 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => MHC CLASS II T-CELL MODULATORY MULTIMERIC POLYPEPTIDES FOR TREATING TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/107244 [patent_app_country] => US [patent_app_date] => 2023-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62911 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18107244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709237 [patent_doc_number] => 20230331850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => MONOCLONAL ANTIBODIES DIRECTED TO PEPTIDE IN THE CONTEXT OF MHC AND METHODS OF MAKING AND USING MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/158362 [patent_app_country] => US [patent_app_date] => 2023-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709237 [patent_doc_number] => 20230331850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => MONOCLONAL ANTIBODIES DIRECTED TO PEPTIDE IN THE CONTEXT OF MHC AND METHODS OF MAKING AND USING MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/158362 [patent_app_country] => US [patent_app_date] => 2023-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19356 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19091001 [patent_doc_number] => 11952431 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-09 [patent_title] => Neutrophil-binding peptides [patent_app_type] => utility [patent_app_number] => 18/089067 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 91 [patent_no_of_words] => 26964 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18089067 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691033 [patent_doc_number] => 20230321224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES [patent_app_type] => utility [patent_app_number] => 18/063610 [patent_app_country] => US [patent_app_date] => 2022-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36282 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18063610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18361212 [patent_doc_number] => 20230142803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => NATURAL KILLER CELLS AND ILC3 CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/056088 [patent_app_country] => US [patent_app_date] => 2022-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18056088 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18466840 [patent_doc_number] => 20230201120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 18/053941 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449623 [patent_doc_number] => 20230190899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => IMMUNE INDUCER [patent_app_type] => utility [patent_app_number] => 17/972055 [patent_app_country] => US [patent_app_date] => 2022-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17972055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18449623 [patent_doc_number] => 20230190899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => IMMUNE INDUCER [patent_app_type] => utility [patent_app_number] => 17/972055 [patent_app_country] => US [patent_app_date] => 2022-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17972055 [rel_patent_id] =>[rel_patent_doc_number] =>)